Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Cintas, Raises Price Target to $353

Morgan Stanley analyst Toni Kaplan maintains Cintas (NASDAQ:CTAS) with a Equal-Weight and raises the price target from $333 to $353.

byBenzinga Newsdesk

July 16, 2021

1 minute read

Morgan Stanley analyst Toni Kaplan maintains Cintas (NASDAQ:CTAS) with a Equal-Weight and raises the price target from $333 to $353.

What Does Okta’s Debt Look Like?

By Benzinga Insights

January 9, 2:16 PM

Shares of Okta Inc. (NASDAQ:OKTA) increased by 35.11% in the past three months. Before having a look at the importance of debt, let's look at how much debt Okta has.

OKTA

FDA
News

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption For U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

By Benzinga Newsdesk

July 6, 7:13 AM

CytoSorbents Corporation (NASDAQ:CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor)

CTSO